NCT03472157RecruitingNot Applicable
Prospective Multicentric, Open Label, Randomized Clinical Trial of Superiority, With Two Arms, Comparing Bariatric Surgery to the Recommended Medical Treatment for NASH
University Hospital, Lille1 site in 1 country100 target enrollmentStarted: June 20, 2018Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Rate of disappearance of NASH without worsening of fibrosis grade
Study Overview
Brief Summary
The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² > BMI ≥ 30 kg/m²) with NASH complicated of advanced fibrosis (F3 and F4 fibrosis grade according to Brunt score).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Provide written informed consent and agree to comply to the study protocol prior to enrolment.
- •BMI and Brunt Fibriosis score:
- •For F3 fibrosis patients: 35>BMI≥ 30kg/m² ; Fibroscan ≥ 9kPa or FibrometreVM ≥0.526 predicting a F3 fibrosis score grade within 1 month before inclusion or F3 fibrosis score grade diagnosed by hepatic biopsy performed before inclusion.
- •For F4 fibrosis patients: 50>BMI≥ 30kg/m² ; Fibroscan ≥ 15kPa predicting a F4 fibrosis score grade within 1 month before inclusion or F4 fibrosis score grade diagnosed by hepatic biopsy performed before inclusion.
- •Fibroscan ≥ 9kPa or FibrometreVM ≥0.526 predicting a F3 or F4 fibrosis score grade within 1 month before inclusion Or F3 or F4 fibrosis score grade diagnosed by hepatic biopsy performed before inclusion.
- •Patient should agree to have one liver biopsy during the screening period (before randomization, the randomization will be permitted after at least a second reading performed by pathologist of CHRU Lille to confirm the histological diagnosis of NASH with advanced fibrosis (F3-F4)) for the diagnosis purpose (if no histological biopsy within 1 month before inclusion is available) and one at the end of the treatment period for assessment of the treatment effects.
- •For patients with cirrhosis, patients must fulfil all the following criteria: Platelets > 125 000, PT > 80 %, Albumin > 35 g/L, MELD score at inclusion < 9, CPT score < 6, No history of previous decompensation, No oesophageal varices (endoscopy), No vascular shunt, ASA score ≤ III, Alcohol consumption lower than 20g/day for women and 30g/day for men.
- •For hypertensive patients, hypertension must be controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study).
- •Female participating in the study must be either of non-child bearing (surgically sterilized at 6 month prior to screening or postmenopausal) or using an efficient contraception: hormonal contraception (including patch, contraceptive ring etc) intra-uterine device or other mechanical contraception
- •Patient agrees to come to the study visits within the protocol-specified delay
Exclusion Criteria
- •Previous history of bariatric surgery (except gastric ring removed for more than 3 years).
- •Decompensated cirrhosis (MELD> 7 CPT score> 5, previous history of decompensation (encephalopathy, ascites, jaundice, varicose vein rupture)
- •Hepatocellular carcinoma
- •Platelets <125 000; TP <80%; bilirubin <20 mmol / l; albumin <35 g / L.
- •Other liver disease: alcohol consumption exceeding 20 g / day for women and 30g / day in men, HBV, HCV, CBP, CSP, autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin.
- •Being processed Cancer (chemotherapy, radiotherapy or hormone therapy)
- •HIV positive patients
- •Patients who had an acute cardiovascular episode, coronary Heart Disease (Angina pectoris, myocardial infarction, revascularization procedure), stroke or TIA (Transient Ischemic Attack) within the 6 months prior to screening Recent cardiovascular events (stroke, myocardial infarcts, etc…) in the past 6 months.
- •Severe chronic respiratory disease.
- •Severe chronic cardiac insufficiency (grade III and IV of NYHA classification).
- •Pregnant or breastfeeding women.
- •Simultaneous enrollment in another clinical trial.
- •Drug abuse within the past year.
- •Patient with contra-indication for bariatric surgery
- •Gastic Banding, Biliopancreatic diversion and all the new bariatric surgery techniques are forbidden because the study design allow only the laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric Bypaass.
- •History of cancer, except:
- •Patients considered in remission for at least 5 years after onset of treatment.
- •Patients Treated and believed to be cured basal or squamous cell carcinoma of the skin or resected carcinoma of the cervix
Arms & Interventions
Bariatric surgery
Experimental
Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.
Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care.
Intervention: Bariatric surgery (Procedure)
Lifestyle therapy
Active Comparator
The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
Intervention: Lifestyle therapy (Other)
Outcomes
Primary Outcomes
Rate of disappearance of NASH without worsening of fibrosis grade
Time Frame: at 60 weeks after randomization
Diagnosis of NASH on the liver biopsy
Secondary Outcomes
- Change in Alanine transaminase (ALT)(at 60 weeks after randomization)
- Percentage of patients achieving at least a 2 point improvement in the NAS (≥2 points) without worsening of fibrosis grade(at 60 weeks after randomization)
- Change in total bilirubin(at 60 weeks after randomization)
- Change in the Brunt fibrosis score,(at 60 weeks after randomization)
- Percentage of patient achieving 5 and 10% of weight loss from randomization to end of treatment.(at 60 weeks after randomization)
- Change in INR (International Normalized Ratio)(at 60 weeks after randomization)
- Change in the SF-36 quality of life score.(at 60 weeks after randomization)
- Change in total cholesterol.(at 60 weeks after randomization)
- Change in the Metavir score(at 60 weeks after randomization)
- Change in Albumin(at 60 weeks after randomization)
- Change in Fasting glucose(at 60 weeks after randomization)
- Change in Glycated haemoglobin(at 60 weeks after randomization)
- Change in the NAS (Nafld Activity Score) score(at 60 weeks after randomization)
- Change in the fibrosis area(at 60 weeks after randomization)
- Percentage of patients with at least one of the following complications(through study completion)
- Change in ALP(at 60 weeks after randomization)
- Change in metabolic profile assessed by HOMA score(at 60 weeks after randomization)
- Change in HDL cholesterol(at 60 weeks after randomization)
- Change in serum triglycerides(at 60 weeks after randomization)
- Change in LDL cholesterol(at 60 weeks after randomization)
- Change in aspartate transaminase (AST)(at 60 weeks after randomization)
- Change in GGT(at 60 weeks after randomization)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Omega Loop Versus Roux-en-Y Gastric BypassObesityNCT02139813Hospices Civils de Lyon256
Completed
Not Applicable
Single-anastomosis Duodeno Ileal Bypass (SADI) Versus Roux-en-Y Gastric BypassObesity, MorbidNCT03610256Hospices Civils de Lyon382
Active, not recruiting
Not Applicable
Sleeve Gastrectomy With Transit Bipartition(SG+TB) Versus Roux-en-Y Gastric Bypass (RYGB) for Type 3 ObesitySevere ObesityNCT04915014University Hospital, Lille320
Terminated
Not Applicable
Analysing Differences in Glycaemic Control Immediately Post Obesity SurgEry (The ADIPOSE Study)ObesityNCT01515059University of Leicester16
Recruiting
Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical PatientIron Deficiency AnemiaNCT04268849Auerbach Hematology Oncology Associates P C104